Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie zur Bewertung unerwünschter Ereignisse, Veränderungen der Krankheitsaktivität und wie sich intravenöses und subkutanes Risankizumab durch den Körper von pädiatrischen Teilnehmern mit mäßig bis schwer aktivem Morbus Crohn bewegt (RISE)

15. Oktober 2026 aktualisiert von: AbbVie

Eine multizentrische Phase-3-Studie zur Bewertung der Pharmakokinetik, Wirksamkeit und Sicherheit von Risankizumab mit offener Induktion, randomisierter doppelblinder Erhaltungstherapie und langfristigen Verlängerungsperioden bei pädiatrischen Probanden (2 bis < 18 Jahre) mit Mäßig bis schwer aktiver Morbus Crohn

Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to < 18 years old who have had intolerance or inadequate response to other therapies.

Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 110 pediatric participants with CD will be enrolled at around 100 sites worldwide.

Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Studienübersicht

Status

Rekrutierung

Bedingungen

Studientyp

Interventionell

Einschreibung (Geschätzt)

110

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Brussels, Belgien, 1020
        • Rekrutierung
        • Hospital Universite Enfants Reine Fabiola /ID# 255112
      • Liège, Belgien, 4000
        • Rekrutierung
        • Groupe Sante CHC - Clinique du MontLegia /ID# 255620
    • Antwerpen
      • Edegem, Antwerpen, Belgien, 2650
        • Rekrutierung
        • Uza /Id# 255114
    • Brussels Capital
      • Brussels, Brussels Capital, Belgien, 1200
        • Rekrutierung
        • Cliniques Universitaires UCL Saint-Luc /ID# 255108
      • Jette, Brussels Capital, Belgien, 1090
        • Rekrutierung
        • Universitair Ziekenhuis Brussel /ID# 255109
    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, Belgien, 3000
        • Rekrutierung
        • Universitair Ziekenhuis Leuven /ID# 255098
      • Plovdiv, Bulgarien, 4002
        • Rekrutierung
        • UMHAT Sveti Georgi EAD /ID# 255386
      • Sofia, Bulgarien, 1606
        • Abgeschlossen
        • Specialized Hospital For Active Treatment Of Children Diseases Prof. Ivan Mitev /ID# 255384
      • Varna, Bulgarien, 9009
        • Rekrutierung
        • UMHAT Multiprofile Hospital for Active Treatment Sveta Marina /ID# 256358
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100045
        • Rekrutierung
        • Beijing Children's Hospital /ID# 256081
      • Beijing, Beijing Municipality, China, 100191
        • Rekrutierung
        • Peking University Third Hospital /ID# 255876
        • Kontakt:
          • Site Coordinator
          • Telefonnummer: +86 010-82266699
    • Guangdong
      • Guangzhou, Guangdong, China, 510620
        • Rekrutierung
        • Guangzhou Medical University Affiliated Women and Children's Medical Center /ID# 255428
      • Guangzhou, Guangdong, China, 510655
        • Rekrutierung
        • The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 270589
    • Henan
      • Zhengzhou, Henan, China, 450018
        • Rekrutierung
        • Henan Children's Hospital Zhengzhou Children's Hospital /ID# 255562
    • Hunan
      • Changsha, Hunan, China, 410007
        • Rekrutierung
        • Hunan Children's Hospital /ID# 255610
    • Jiangxi
      • Nanchang, Jiangxi, China, 330006
        • Rekrutierung
        • Jiangxi Provincial Children's Hospital /ID# 255564
    • Liaoning
      • Shenyang, Liaoning, China, 110022
        • Rekrutierung
        • Shengjing Hospital of China Medical University /ID# 255563
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200062
        • Rekrutierung
        • Children's Hospital of Shanghai /ID# 255531
      • Shanghai, Shanghai Municipality, China, 200065
        • Rekrutierung
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 255688
    • Bavaria
      • Munich, Bavaria, Deutschland, 80337
        • Rekrutierung
        • Dr. von Haunerschen Kinderspital /ID# 255577
    • North Rhine-Westphalia
      • Münster, North Rhine-Westphalia, Deutschland, 48149
        • Rekrutierung
        • Universitaetsklinikum Muenster /ID# 256762
      • Paris, Frankreich, 75015
        • Rekrutierung
        • AP-HP - Hopital Necker /ID# 255608
    • Centre-Val de Loire
      • Tours, Centre-Val de Loire, Frankreich, 37044
        • Rekrutierung
        • CHRU Tours - Hopital Gatien de Clocheville /ID# 255052
    • New Aquitaine
      • Bordeaux, New Aquitaine, Frankreich, 33076
        • Rekrutierung
        • Chu Bordeaux - Hopital Pellegrin /ID# 257060
    • Occitanie
      • Toulouse, Occitanie, Frankreich, 31059
        • Rekrutierung
        • CHU Toulouse - Hopital Paule de Viguier /ID# 255609
    • Rhone
      • Bron, Rhone, Frankreich, 69500
        • Rekrutierung
        • Hospices Civils de Lyon - Hopital Femme Mere Enfant /ID# 255443
    • Central District
      • Petah Tikva, Central District, Israel, 4920235
        • Rekrutierung
        • Schneider Children's Medical Center /ID# 254950
    • Jerusalem
      • Jerusalem, Jerusalem, Israel, 91031
        • Rekrutierung
        • Shaare Zedek Medical Center /ID# 254951
      • Messina, Italien, 98125
        • Rekrutierung
        • Azienda Ospedaliera Universitaria Gaetano Martino /ID# 255044
    • Genova
      • Genoa, Genova, Italien, 16147
        • Rekrutierung
        • IRCCS Istituto Giannina Gaslini /ID# 255262
    • Napoli
      • Naples, Napoli, Italien, 80131
        • Rekrutierung
        • Azienda Ospedaliera Universitaria Federico II - Naples /ID# 255045
    • Roma
      • Rome, Roma, Italien, 00165
        • Rekrutierung
        • Ospedale Pediatrico Bambino Gesu /ID# 255043
    • Aichi-ken
      • Ōbu, Aichi-ken, Japan, 474-8710
        • Rekrutierung
        • Aichi Children's Health And Medical Center /ID# 272085
    • Chiba
      • Kashiwa-shi, Chiba, Japan, 277-0871
        • Rekrutierung
        • Tsujinaka Hospital - Kashiwanoha /ID# 268409
    • Fukuoka
      • Kurume-shi, Fukuoka, Japan, 830-0011
        • Rekrutierung
        • Kurume University Hospital /ID# 268418
    • Gunma
      • Maebashi, Gunma, Japan, 371-8511
        • Rekrutierung
        • Gunma University Hospital /ID# 270560
    • Kumamoto
      • Kumamoto, Kumamoto, Japan, 861-8520
        • Rekrutierung
        • Japanese Red Cross Kumamoto Hospital /ID# 268586
    • Osaka
      • Izumi-Shi, Osaka, Japan, 594-1101
        • Rekrutierung
        • Osaka Women's and Children's Hospital /ID# 268419
    • Saitama
      • Saitama-shi, Saitama, Japan, 330-8777
        • Rekrutierung
        • Saitama Children's Medical Center /ID# 268410
    • Tokyo
      • Bunkyo-ku, Tokyo, Japan, 113-8519
        • Rekrutierung
        • Institute of Science Tokyo Hospital /ID# 269175
      • Fuchu-shi, Tokyo, Japan, 183-8561
        • Rekrutierung
        • Tokyo Metropolitan Children's Medical Center /ID# 268415
      • Setagaya City, Tokyo, Japan, 157-8535
        • Rekrutierung
        • National Center For Child Health And Development /ID# 268420
    • Alberta
      • Calgary, Alberta, Kanada, T3B 6A8
        • Rekrutierung
        • Alberta Children's Hospital /ID# 255357
      • Edmonton, Alberta, Kanada, T6G 1C9
        • Rekrutierung
        • Edmonton Clinic Health Academy /ID# 255361
    • British Columbia
      • Vancouver, British Columbia, Kanada, V6H 3V4
        • Rekrutierung
        • BC Children's Hospital /ID# 255359
    • Ontario
      • London, Ontario, Kanada, N6A 5W9
        • Rekrutierung
        • London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 258598
    • North Holland
      • Amsterdam, North Holland, Niederlande, 1105 AZ
        • Rekrutierung
        • Amsterdam University Medical Center /ID# 254827
    • Kuyavian-Pomeranian Voivodeship
      • Torun, Kuyavian-Pomeranian Voivodeship, Polen, 87-100
        • Abgeschlossen
        • Gastromed Sp. z o.o /ID# 255939
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polen, 04-730
        • Rekrutierung
        • Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 255938
      • Dorado, Puerto Rico, 00646
        • Rekrutierung
        • Puerto Rico Health Institute /ID# 255071
      • San Juan, Puerto Rico, 00909-1711
        • Rekrutierung
        • Clinical Research Puerto Rico /ID# 266479
    • Stockholm County
      • Stockholm, Stockholm County, Schweden, 118 83
        • Rekrutierung
        • Sodersjukhuset /ID# 255239
      • Stockholm, Stockholm County, Schweden, 171 76
        • Rekrutierung
        • Astrid Lindgrens Barnsjukhus /ID# 255240
    • Västra Götaland County
      • Gothenburg, Västra Götaland County, Schweden, 413 46
        • Rekrutierung
        • Sahlgrenska Universitetssjukhuset /ID# 255236
        • Kontakt:
          • Site Coordinator
          • Telefonnummer: +46313435865
      • Bern, Schweiz, 3010
        • Rekrutierung
        • Inselspital, Universitaetsspital Bern /ID# 255321
    • Canton of Zurich
      • Zurich, Canton of Zurich, Schweiz, 8032
        • Rekrutierung
        • Kinderspital Zurich - Eleonorenstiftung /ID# 255337
      • Madrid, Spanien, 28009
        • Abgeschlossen
        • Hospital Infantil Universitario Nino Jesus /ID# 255012
      • Málaga, Spanien, 29011
        • Rekrutierung
        • Hospital Regional Universitario de Malaga /ID# 257553
    • A Coruna
      • Ferrol, A Coruna, Spanien, 15405
        • Rekrutierung
        • Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 255614
      • Daegu, Südkorea, 41404
        • Rekrutierung
        • Kyungpook National University Chilgok Hospital /ID# 255817
    • Seoul Teugbyeolsi
      • Seoul, Seoul Teugbyeolsi, Südkorea, 03080
        • Rekrutierung
        • Seoul National University Hospital /ID# 255318
      • Seoul, Seoul Teugbyeolsi, Südkorea, 06351
        • Rekrutierung
        • Samsung Medical Center /ID# 255284
      • Seoul, Seoul Teugbyeolsi, Südkorea, 03722
        • Rekrutierung
        • Yonsei University Health System - Severance Hospital /ID# 256976
      • Changhua City, Changhua County, Taiwan, 50006
        • Rekrutierung
        • Changhua Christian Hospital /ID# 256082
      • Taipei, Taiwan, 100
        • Rekrutierung
        • National Taiwan University Hospital /ID# 255679
    • Praha 17
      • Prague, Praha 17, Tschechien, 128 00
        • Abgeschlossen
        • Vseobecna Fakultni nemocnice v Praze /ID# 256096
    • Praha 5
      • Prague, Praha 5, Tschechien, 150 06
        • Abgeschlossen
        • Fakultni nemocnice Motol a Homolka /ID# 256547
      • Ankara, Türkei (türkiye), 06560
        • Rekrutierung
        • Gazi University Medical Faculty /ID# 255086
      • Istanbul, Türkei (türkiye), 34453
        • Rekrutierung
        • Sariyer Hamidiye Etfal Egitim Ve Araştirma Hastanesi /ID# 257143
      • Istanbul, Türkei (türkiye), 34899
        • Rekrutierung
        • Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 261020
      • Kocaeli, Türkei (türkiye), 41380
        • Rekrutierung
        • Kocaeli University Med Faculty /ID# 256922
    • Arizona
      • Phoenix, Arizona, Vereinigte Staaten, 85016-7710
        • Rekrutierung
        • Phoenix Children's Hospital /ID# 255766
    • Arkansas
      • Little Rock, Arkansas, Vereinigte Staaten, 72202
        • Abgeschlossen
        • Arkansas Children's Hospital /ID# 255762
    • California
      • Oakland, California, Vereinigte Staaten, 94609
        • Rekrutierung
        • UCSF Benioff Children's Hospital - Oakland /ID# 258327
    • Colorado
      • Aurora, Colorado, Vereinigte Staaten, 80045
        • Rekrutierung
        • Children's Hospital Colorado - Aurora /ID# 255764
    • Florida
      • Orlando, Florida, Vereinigte Staaten, 32806-1141
        • Rekrutierung
        • Arnold Palmer Hospital for Children Center Digestive Health and Nutrition-Orland /ID# 255437
    • Indiana
      • Indianapolis, Indiana, Vereinigte Staaten, 46202
        • Rekrutierung
        • Indiana University Health Riley Hospital for Children /ID# 256454
    • Massachusetts
      • Waltham, Massachusetts, Vereinigte Staaten, 02451
        • Rekrutierung
        • Massachusetts General Hospital - Mass General Waltham /ID# 255767
    • Minnesota
      • Minneapolis, Minnesota, Vereinigte Staaten, 55413-2195
        • Rekrutierung
        • MNGI Digestive Health, P. A. /ID# 255366
    • New Jersey
      • Morristown, New Jersey, Vereinigte Staaten, 07960
        • Rekrutierung
        • Goryeb Childrens Hospital /ID# 256452
    • New York
      • New York, New York, Vereinigte Staaten, 10029
        • Rekrutierung
        • Icahn School of Medicine at Mount Sinai /ID# 254880
    • Ohio
      • Cleveland, Ohio, Vereinigte Staaten, 44195
        • Rekrutierung
        • Cleveland Clinic - Cleveland /ID# 256453
        • Kontakt:
          • Site Coordinator
          • Telefonnummer: 216-636-2007
      • Birmingham, Vereinigtes Königreich, B4 6NH
        • Rekrutierung
        • Birmingham Women's and Children's NHS Foundation Trust /ID# 255759
    • England
      • Sheffield, England, Vereinigtes Königreich, S10 2TH
        • Rekrutierung
        • Sheffield Children's Hospital NHS Foundation Trust /ID# 255758
        • Kontakt:
          • Site Coordinator
          • Telefonnummer: +44 114 273 0522
    • Greater London
      • London, Greater London, Vereinigtes Königreich, E1 2ES
        • Rekrutierung
        • Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 255757

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

2 Jahre bis 17 Jahre (Kind)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Pediatric individuals, 2 to < 18 years old
  • Must have moderately to severely active CD, as defined by the PCDAI score > 30 assessed at Baseline
  • Must have endoscopic evidence of mucosal inflammation as documented by the SES-CD of ≥ 6 for ileocolonic or colonic disease (or SES-CD of ≥ 4 for isolated ileal disease)
  • Demonstrated intolerance or inadequate response to one or more of the following categories of drugs: aminosalicylates (This drug class is not sufficient for eligibility for subjects in France, Italy, Netherlands, Spain, and Sweden), oral locally acting corticosteroids, systemic steroids (prednisone or equivalent), IMMs, and/or biologic therapies

Exclusion Criteria:

  • History of hereditary fructose intolerance (a rare genetic condition) or an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class

  • Any of the following medical disorders:

    1. Current diagnosis of ulcerative colitis, indeterminate colitis, or monogenic IBD.

    2. A diagnosis of CD prior to 2 years of age.

    3. A diagnosis or suspected diagnosis of a primary immunodeficiency.

    4. Currently known complications of CD such as:

      • Active abscess (abdominal or perianal);
      • Symptomatic bowel strictures;
      • > 2 missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum;
      • Fulminant colitis;
      • Toxic megacolon;
      • Or any other manifestation that might require surgery while enrolled in the study.
    5. Ostomy or ileoanal pouch.

    6. Diagnosis of short gut or short bowel syndrome.

    7. Surgical bowel resection within the past 3 months prior to Baseline (excluding gastrointestinal surgeries which are not bowel resections such as appendectomy or ostomy closure), or a history of >3 bowel resections.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Sequenzielle Zuweisung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: PK Cohort 1: SS3 Dose A

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Andere Namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere Namen:
  • ABBV-066
  • SKYRIZI
Experimental: PK Cohort 1: SS3 Dose B

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Andere Namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere Namen:
  • ABBV-066
  • SKYRIZI
Experimental: PK Cohort 2: SS1

Cohort 2 will enroll participants aged 2 to less than 6 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.

Intravenous (IV) Infusion

Andere Namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere Namen:
  • ABBV-066
  • SKYRIZI
Experimental: PK Cohort 2: SS3 Dose A

Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Andere Namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere Namen:
  • ABBV-066
  • SKYRIZI
Experimental: PK Cohort 2: SS3 Dose B

Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Andere Namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere Namen:
  • ABBV-066
  • SKYRIZI
Experimental: Expansion Cohort 3: SS3 Dose A

Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Andere Namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere Namen:
  • ABBV-066
  • SKYRIZI
Experimental: Expansion Cohort 3: SS3 Dose B

Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Andere Namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere Namen:
  • ABBV-066
  • SKYRIZI
Experimental: PK Cohort 1: SS1

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All participants who complete SS1 are eligible to enter SS2.

Intravenous (IV) Infusion

Andere Namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere Namen:
  • ABBV-066
  • SKYRIZI
Experimental: PK Cohort 1: SS2 Dose A

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Andere Namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere Namen:
  • ABBV-066
  • SKYRIZI
Experimental: PK Cohort 1: SS2 Dose B

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Andere Namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere Namen:
  • ABBV-066
  • SKYRIZI
Experimental: PK Cohort 2: SS2 Dose A

Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Andere Namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere Namen:
  • ABBV-066
  • SKYRIZI
Experimental: PK Cohort 2: SS2 Dose B

Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Andere Namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere Namen:
  • ABBV-066
  • SKYRIZI
Experimental: Expansion Cohort 3: SS1

Cohort 3 will enroll participants aged 2 to less than 18 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.

Intravenous (IV) Infusion

Andere Namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere Namen:
  • ABBV-066
  • SKYRIZI
Experimental: Expansion Cohort 3: SS2 Dose A

Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Andere Namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere Namen:
  • ABBV-066
  • SKYRIZI
Experimental: Expansion Cohort 3: SS2 Dose B

Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Andere Namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere Namen:
  • ABBV-066
  • SKYRIZI

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Cohort 3 (Substudy 2): Percentage of Participants Achieving Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission
Zeitfenster: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 64 weeks
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per Simple Endoscopic Score for Crohn's Disease (SES-CD)
Zeitfenster: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 64 weeks
Cohorts 1 & 2: Maximum Observed Serum Concentration (Cmax) of Risankizumab
Zeitfenster: Up to approximately Week 64

Cmax of risankizumab

Up to approximately Week 64
Cohorts 1 & 2: Time to Cmax (Tmax) of Risankizumab
Zeitfenster: Up to approximately 64 weeks

Tmax of risankizumab

Up to approximately 64 weeks
Cohorts 1 & 2: Area Under the Serum Concentration-Time Curve Over the Dosing Interval (AUCtau) of Risankizumab
Zeitfenster: Up to approximately 64 weeks

AUCtau of risankizumab

Up to approximately 64 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Cohort 3 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Zeitfenster: At 12 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 12 weeks
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Zeitfenster: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 12 weeks
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Zeitfenster: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 12 weeks
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Zeitfenster: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 64 weeks
Cohort 3 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Zeitfenster: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit.

At 64 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving PCDAI Clinical Remission
Zeitfenster: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 64 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per SES-CD
Zeitfenster: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 64 weeks
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Zeitfenster: At 12 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 12 weeks
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Zeitfenster: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 12 weeks
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Zeitfenster: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 12 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Zeitfenster: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 64 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Zeitfenster: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit.

At 64 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: ABBVIE INC., AbbVie

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

11. Dezember 2023

Primärer Abschluss (Geschätzt)

1. April 2029

Studienabschluss (Geschätzt)

1. April 2029

Studienanmeldedaten

Zuerst eingereicht

10. August 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

10. August 2023

Zuerst gepostet (Tatsächlich)

16. August 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

20. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

15. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • M16-194
  • 2022-502050-14-00 (Andere Kennung: EU CT)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

IPD-Sharing-Zeitrahmen

For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

IPD-Sharing-Zugriffskriterien

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren